

JULY 2021

Does early treatment with highly effective DMT improve prognosis for people with MS?

WELCOME TO THE DELIVER-MS NEWSLETTER

This month has seen a pick up in recruitment in some sites (Nikos in Nottingham climbed off the naughty step - see below). But we remind you that we are still keen for all sites to <u>aim for at least one new enrolment per month</u>. The UK out performed the US this month, but with the summer holidays approaching we need to keep up our momentum if we want to close the gap!


We are delighted to highlight another new site, Edinburgh, this month. We loved welcoming our first Scottish site to DELIVER-MS and they have truly hit the ground running. We hear from PI Don Mahad and the team (see below).





DELIVER-MS ENROLLMENT LAST CALENDAR MONTH

(overall recruitment shown at the end of the newsletter)



DELIVER-MS FOCUS: EDINBURGH

We asked the Edinburgh DELIVER-MS team to share their experience:

"The team here are really excited to be involved in the DELIVER-MS trial. Based at the Anne Rowling Clinic, our DELIVER-MS team consists of PI: Don Mahad, Lead Research Nurse: Dawn Lyle, Research Practitioner: Tanya Van Der Westhuizen and Clinical Fellow: Zack Hassan. Collectively we help deliver several research studies at site and clinical trials into neurological conditions specifically in MS and MND patient groups.

We are a purpose-built research clinic which hosts NHS clinics using close working relationship with our NHS colleagues to offer patients attending the clinic an opportunity to get involved in research.

We were very keen to get involved in DELIVER-MS as the question is an important one and one that is meaningful for our patients who understand why the study is being undertaken. It is good to be promoting research at an early stage in their disease pathway.

We have had a positive response from patients and have been taken aback at the willingness of patients to consider participating, even

though they are newly diagnosed.



TanyaVDW and bottom crouching Zack H


Even if participants already have their mind set on a specific drug, they still want to take part in the observational arm.

The pandemic has made clinicians think more carefully about the risks and benefits of DMTs. If more research can be done into the benefits of different DMT regimens, doctors and patients could have more informed discussions and more personalised care.

As a team we continue to enjoy contributing to the study, the trial office has been really supportive and our participants really enthusiastic."

NEWS AND UPDATES

- We are delighted to welcome back Harriet (UK Project Manager) from her maternity leave, and equally chuffed that Aimee remains part of the team.
- If a patient switches to a new DMT, or stops their current DMT, please detail the reasons and start and stop dates on the DMT summary form.
- § All sites: <u>please do not send biobank samples on Fridays</u> as they cannot be processed.
- All sites: Please remember to keep your serum storage logs up to date and send to Aimee (UK) or Praneeta (US) monthly
- US sites: please send Praneeta/Sarah copies of any FedEx invoices you receive we apologize for any inconvenience. Cardinal Health assures us that the problem has been resolved and that it is fine to continue to send samples to UAB.



FINAL THOUGHTS

We are well over half way in DELIVER MS enrolment and are entering the final straight. We continue to ask you to collectively push enrollment in the coming months, so we can demonstrate to our funders that study enrollment can be completed over the next year."

Relevant Links

Our website is:

www.deliver-ms.com

Our mailing address is:

planchs@ccf.org (US) and harriet.howard@nottingham.ac.uk (UK)